Xilio Therapeutics, INC 8-K filings

Xilio Therapeutics announced second quarter 2026 financial results, highlighting FDA clearance for XTX501 IND and advancing masked T cell engager programs, with cash runway extending into Q1 2028.

Xilio Therapeutics reported Q1 2026 financial results, highlighting pipeline progress with XTX501 and masked T cell engagers, and extended its cash runway into early 2028.

Xilio Therapeutics has appointed Dr. Cheryl Blanchard as a Class III director and chair of the Compensation Committee, succeeding the outgoing Christina Rossi.

Xilio Therapeutics announced its Q4 and full-year 2025 financial results, highlighting significant pipeline progress and an extended cash runway through 2027.

Xilio Therapeutics will implement a 1-for-14 reverse stock split to meet Nasdaq's minimum bid price requirement, effective March 13, 2026.

Xilio Therapeutics' stockholders have approved a reverse stock split of its common shares, with the exact ratio and timing at the board's discretion.

Xilio Therapeutics announced the pricing of an underwritten offering of pre-funded warrants to purchase 74.8 million common shares, expecting to raise approximately $37.1 million in net proceeds.

Xilio Therapeutics announced strong cash reserves, key development milestones, and a new board chair, extending its cash runway into Q2 2027.

Xilio Therapeutics, Inc. announced the exercise of Series B warrants generating $35.8 million and provided an updated cash runway into Q2 2027.

Xilio Therapeutics, Inc. stockholders approved a new 2025 Stock Incentive Plan and a one-time repricing of certain employee stock options at a special meeting on November 21, 2025.

Xilio Therapeutics reported its Q3 2025 financial results and significant pipeline advancements, including promising clinical data for vilastobart and efarindodekin alfa, extending its cash runway into Q1 2027.

Xilio Therapeutics announced new clinical and preclinical data across its immuno-oncology pipeline, highlighting positive Phase 2 results for vilastobart in colorectal cancer and progress in its T cell engager platform.

Xilio Therapeutics' common stock will transfer to The Nasdaq Capital Market on October 6, 2025, after failing to meet the $1.00 minimum bid price requirement, granting the company an additional 180 days to regain compliance.

Xilio Therapeutics announced the initiation of Phase 2 for its tumor-activated IL-12, efarindodekin alfa (XTX301), and achieved a $17.5 million development milestone from Gilead, extending its cash runway.

Xilio Therapeutics, Inc. received a Nasdaq deficiency letter for failing to meet the minimum $10 million stockholders' equity requirement, adding to an existing minimum bid price non-compliance.

Xilio Therapeutics announced its second quarter 2025 financial results and pipeline updates, highlighting positive Phase 2 vilastobart data and a strengthened cash position.

Xilio Therapeutics, Inc. announced the successful election of Class I directors, approval of a significant increase in authorized common stock, and adoption of officer exculpation provisions at its 2025 annual meeting of stockholders.

Xilio Therapeutics, Inc. announced the expansion of its Board of Directors to ten members and the appointment of Dr. Akintunde Bello as a Class II director, effective June 10, 2025.

Xilio Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $50.0 million public offering of pre-funded and common stock warrants, aiming to extend its cash runway through the third quarter of 2026.

Xilio Therapeutics announced updated positive Phase 2 clinical trial data for its tumor-activated anti-CTLA-4 therapy, vilastobart, in combination with atezolizumab, demonstrating a 26% objective response rate and a differentiated safety profile in heavily pre-treated metastatic microsatellite stable colorectal cancer patients without liver metastases.

Xilio Therapeutics reports encouraging Phase 2 data for vilastobart in MSS CRC and advances multiple masked T cell engager programs, alongside Q1 2025 financial results.

Xilio Therapeutics receives notification from Nasdaq regarding non-compliance with minimum bid price requirement, potentially leading to delisting.

Xilio Therapeutics has entered into a sales agreement with Leerink Partners to sell up to $50 million of its common stock through an at-the-market offering.

Xilio Therapeutics reports encouraging Phase 2 data for vilastobart in MSS CRC patients and announces a collaboration with AbbVie to develop novel tumor-activated immunotherapies.

Xilio Therapeutics and AbbVie have entered into a collaboration and option agreement potentially worth up to $2.1 billion to develop novel tumor-activated immunotherapies.

Xilio Therapeutics announced positive initial results from a Phase 2 trial of its tumor-activated drug, vilastobart, combined with atezolizumab, showing a 27% preliminary response rate in patients with advanced microsatellite stable colorectal cancer.

Xilio Therapeutics completed a $25 million private placement with Gilead, announced positive preliminary Phase 1 data for XTX301, and plans to present Phase 2 data for vilastobart at ASCO GI in January 2025.

Xilio Therapeutics reported encouraging initial Phase 1C clinical trial data for vilastobart in combination with atezolizumab, along with third quarter 2024 financial results and pipeline updates.

Xilio Therapeutics has received a notice from Nasdaq stating that its stock price has fallen below the minimum bid price of $1.00, putting the company at risk of delisting.

Xilio Therapeutics announced progress in its clinical trials for XTX101 and XTX301, along with its second quarter 2024 financial results, highlighting a cash runway into the second quarter of 2025.